Enterprise Therapeutics

Enterprise Therapeutics is a private, clinical-stage biotech founded in 2015 and headquartered in Brighton, UK, targeting major respiratory diseases. Its core strategy involves developing small molecule therapies that address mucus congestion, a key pathological feature in cystic fibrosis, asthma, and COPD. The company's lead asset, ETD001, has completed a Phase 1 study and received Rare Pediatric Disease Designation in the US, marking significant progress. Backed by a syndicate of leading life science investors, Enterprise is advancing its pipeline toward later-stage clinical development.

Focus on inhaled small molecules targeting ion transport (e.g., ENaC inhibition) and mucus biology to rehydrate airways and restore mucociliary clearance in respiratory diseases.

In cystic fibrosis, Enterprise competes with Vertex's dominant CFTR modulators and other companies developing correctors, amplifiers, and alternative approaches like gene therapy. In the ENaC blocker space, it faces competition from other biotechs (e.g., Santhera/Patara) and past failures that color perception of the target. In broader respiratory markets, it would compete with large pharma's biologics and anti-inflammatories.